Momenta clears a PhII hurdle on nipo — but one big rival remains well in the lead in this packed field
Momenta $MNTA had a few things to prove going into its interim analysis of a Phase II study for its drug nipocalimab (M281) in treating generalized myasthenia gravis.
The small study had to provide some clear evidence of substantial efficacy over a placebo. They also needed a clean safety profile that pointed the way to a potential superior profile over the competition it faces in the clinic — particularly with argenx’s rival drug being teed up for an FDA filing in the wake of a successful Phase III.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.